Forum Karczmy Bezdennego Kufla

wlkleo00jah

Another interesting study is called, Continuous hyperthermic peritoneal perfusion with cisplatin for the treatment of peritoneal mesothelioma. By Ma GY, Bartlett DL, Reed E, Figg WD, Lush RM, Lee KB, Libutti SK, Alexander HR. – Metabolism Section, National Cancer Institute, National Institutes of [link widoczny dla zalogowanych] Health, Bethesda, [link widoczny dla zalogowanych] Maryland 20892. Cancer J Sci Am. 1997 May-Jun;3(3):174-9. Here is an excerpt: Abstract – PURPOSE: Peritoneal mesothelioma remains a difficult therapeutic challenge. Aggressive debulking combined with continuous hyperthermic peritoneal perfusion (CHPP) using cisplatin (CDDP) is a novel strategy for the treatment of peritoneal mesothelioma, allowing high regional delivery of chemotherapeutics and hyperthermia while minimizing systemic toxicity. PATIENTS AND METHODS: From June 1993 to May 1996, 10 patients with peritoneal mesothelioma (six men, four women; mean age 40 years, range [link widoczny dla zalogowanych] 15-57) underwent tumor debulking followed by a 90-minute CHPP. CHPP parameters included mean initial CDDP of 120 micrograms/mL (range 81-166), perfusate volume 5.2 L (range 4-7), flow 1.5 L/min, [link widoczny dla zalogowanych] intraperitoneal temperature at three locations-41.5 degrees C, 40.5 degrees C, 41.1 degrees C, and core temperature 38.4 [link widoczny dla zalogowanych] degrees C (range 37.2 degrees C-39.5 degrees C). Nine of 10 patients had malignant peritoneal mesothelioma, eight with associated ascites, while the tenth had a symptomatic, multiply recurrent benign peritoneal mesothelioma. Nine of 10 patients were optimally debulked. Pharmacokinetics were performed on blood and perfusate samples on nine patients; CDDP [link widoczny dla zalogowanych] levels were quantitated by atomic absorption spectroscopy. RESULTS: Total perfusate cisplatin AUC was a mean of 21-fold higher (range 2- to 116-fold) than total serum cisplatin AUC, and serum CDDP behaved similarly to systemically administered CDDP. Median follow-up after CHPP is 10 months (range 2-32), with no treatment-related mortality. In eight optimally debulked patients there is no evidence of recurrent disease clinically or by CT or MRI. Seven patients with symptomatic ascites have been completely palliated.
CONCLUSIONS: CHPP with CDDP is well tolerated with no significant regional toxicity. Because favorable CDDP pharmacokinetics suggest the potential for enhanced CDDP tumoricidal effect during CHPP, tumor debulking and CHPP may represent an effective strategy for the treatment of peritoneal mesothelioma.
Another interesting study is called, The diagnostic distinction between malignant mesothelioma of the pleura and adenocarcinoma of the lung as defined by a monoclonal antibody (B72.3). by C. A. Szpak, W. W. Johnston, V. Roggli, J. Kolbeck, S. C. Lottich, R. Vollmer, A. Thor, and J. Schlom – Am J Pathol. 1986 February; 122(2): 252260. Here is an excerpt: Abstract – The correct distinction between malignant mesothelioma of the pleura and adenocarcinoma of the lung [link widoczny dla zalogowanych] has become increasingly complex, with a variety of histochemical, [link widoczny dla zalogowanych] immunohistochemical, and ultrastructural studies to be performed on biopsy material. The reliability of immunohistochemical studies has been hampered by the use of polyclonal antisera to “carcinoembryonic antigen (CEA)” and keratin. Hybridoma technology now offers monoclonal antibodies (MAbs) in unlimited quantity and standardized quality to selective ranges [link widoczny dla zalogowanych] of specific antigenic determinants. MAb B72.3, generated against a membrane-enriched fraction [link widoczny dla zalogowanych] of human metastatic breast carcinoma, was used to distinguish malignant mesothelioma of the pleura from adenocarcinoma of the lung in tissue sections and was compared in terms of diagnostic utility with polyclonal anti-keratin and anti-CEA to make the same distinction. Reactivity with MAb B72.3 in at least 10% of tumor cells or more was noted in 19 of 22 adenocarcinomas of the lung (P greater than 0.0001), whereas none of [link widoczny dla zalogowanych] the 20 cases of malignant mesothelioma demonstrated comparable reactivity. Furthermore, MAb B72.3 [link widoczny dla zalogowanych] showed no reactivity with benign mesothelial proliferations. MAb B72.3 thus appears to be an appropriate diagnostic adjunct capable of discriminating between these malignancies.
We all owe a debt of gratitude to these fine researchers. If you found any of these excerpts interesting, please read the studies in their entirety.
相关的主题文章:

[link widoczny dla zalogowanych]

[link widoczny dla zalogowanych]

[link widoczny dla zalogowanych]